Business Context and Reporting Period
This Form 6-K filing by Hong Kong Pharma Digital Technology Holdings Limited (the "Company") covers the month of October 2025, with a report date of October 6, 2025. The filing primarily addresses significant changes to the Company's executive leadership and board composition.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance changes and executive compensation terms rather than financial performance data.
Material Changes
The Company experienced a complete turnover of its top executive management team effective October 6, 2025:
- Resignations: Mr. Wong Lap Sun (CEO), Mr. Zhifang Zhang (Executive Director), and Mr. Kwok Man Bun (CFO) resigned for personal reasons. Ms. Yingying Li (COO) had previously resigned on April 30, 2025, also for personal reasons. The Board confirmed no disagreements regarding operations or policies.
- Appointments:
- Mr. Chenyu Liang appointed as Director and Chief Executive Officer.
- Ms. Shu Liu appointed as Chief Financial Officer.
- Mr. Zifeng Wang appointed as Chief Strategy Officer.
Guidance, Outlook, and Management Commentary
The filing outlines the professional backgrounds of the new leadership to support strategic execution:
- Mr. Liang (CEO): Former CEO of Jiangsu Miaodong Trading Group (2023-2025) with experience in multinational operations and supply chain management.
- Ms. Liu (CFO): Former CEO of Shenzhen Yingdatongli Investment Group and Investment Advisor at Guosen Securities, with expertise in financial compliance and internal controls.
- Mr. Wang (CSO): Over 25 years of experience in biotechnology and enterprise management, currently Chairman of Zhejiang Shengyan Biotechnology Co., Ltd.
Compensation: Annual base salaries were established as HKD 100,000 for the CEO, HKD 100,000 for the CFO, and HKD 70,000 for the Chief Strategy Officer.
Investor Verification Checklist
- Verify the operational status of the Company following the resignation of the entire prior executive team.
- Review the full text of the employment agreements (Exhibits 99.1, 99.2, and 99.3) for additional terms beyond base salary.
- Confirm the Company's current liquidity position, as no financial data was disclosed in this filing.
- Assess the strategic fit of the new Chief Strategy Officer's biotechnology background with the Company's stated business model.